Європейський Союз - італійська - EMA (European Medicines Agency)

actavis group ptc ehf   - pioglitazone cloridrato - diabete mellito, tipo 2 - farmaci usati nel diabete - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin. a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4. dopo l'inizio della terapia con pioglitazone, i pazienti devono essere rivisti dopo 3 a 6 mesi per valutare l'adeguatezza della risposta al trattamento (e. riduzione dell'hba1c). nei pazienti che non mostrano una risposta adeguata, pioglitazone deve essere interrotto. alla luce di potenziali rischi di un prolungato di terapia, i medici prescrittori devono confermare alla successiva routine di recensioni che il beneficio di pioglitazone è mantenuto (vedere la sezione 4.

Європейський Союз - італійська - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - diabete mellito, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Італія - італійська - Ministero della Salute

ceva salute animale s.p.a. - paracetamolo - paracetamolo - 200 mg/ml, paracetamolo - 400 mg/ml - paracetamol

Європейський Союз - італійська - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Європейський Союз - італійська - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Швейцарія - італійська - Swissmedic (Swiss Agency for Therapeutic Products)

strides pharma international ag - macrogolum 3350, natrii chloridum, natrii hydrogenocarbonas, kalii chloridum - polvere - pulver: macrogolum 3350 13.125 g, natrii chloridum 350.7 mg, natrii hydrogenocarbonas 178.5 mg, kalii chloridum 46.6 mg, acesulfamum kalicum, aromatica (zitrone), ad pulverem pro charta corresp. natrium 190 mg et kalium 24.3 mg. - macrgol fairmed junior: koprostase bei kindern (2 bis 11 jahre). macrogol fairmed junior darf maximal an 7 tagen hintereinander angewendet werden.; symptomatische behandlung der obstipation bei kindern (2 bis 11 jahre). macrogol fairmed junior darf ohne ärztliche empfehlung nicht länger als 3 monate angewendet werden, da für die langzeitbehandlung keine erfahrungen vorliegen.; macrogol fairmed:symptomatische behandlung der obstipation bei erwachsenen.; macrogol fairmed darf ohne ärztliche empfehlung nicht länger als 3 monate angewendet werden, da für die langzeitbehandlung keine erfahrungen vorliegen.; symptomatische behandlung der koprostase bei erwachsenen. die bei koprostase verwendete höhere dosis darf maximal während 3 tagen angewendet werden. - synthetika

Швейцарія - італійська - Swissmedic (Swiss Agency for Therapeutic Products)

strides pharma international ag - macrogolum 3350, natrii chloridum, natrii hydrogenocarbonas, kalii chloridum - polvere - macrogolum 3350 6.563 g, natrii chloridum 175.4 mg, natrii hydrogenocarbonas 89.3 mg, kalii chloridum 23.3 mg, acesulfamum kalicum, aromatica (zitrone), ad pulverem pro charta corresp. natrium 95 mg et kalium 12.11 mg. - macrgol fairmed junior: koprostase bei kindern (2 bis 11 jahre). macrogol fairmed junior darf maximal an 7 tagen hintereinander angewendet werden.; symptomatische behandlung der obstipation bei kindern (2 bis 11 jahre). macrogol fairmed junior darf ohne ärztliche empfehlung nicht länger als 3 monate angewendet werden, da für die langzeitbehandlung keine erfahrungen vorliegen.; macrogol fairmed:symptomatische behandlung der obstipation bei erwachsenen.; macrogol fairmed darf ohne ärztliche empfehlung nicht länger als 3 monate angewendet werden, da für die langzeitbehandlung keine erfahrungen vorliegen.; symptomatische behandlung der koprostase bei erwachsenen. die bei koprostase verwendete höhere dosis darf maximal während 3 tagen angewendet werden. - synthetika

Європейський Союз - італійська - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Італія - італійська - Ministero della Salute

voco gmbh - cementi provvisori e definitivi da restauro odontoiatrico

Італія - італійська - Ministero della Salute

kettenbach gmbh & co. kg - alginati ed altri materiali per impronte odontoiatriche